GSA Capital Partners’s Taysha Gene Therapies TSHA Stock Holding History

GSA Capital Partners’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$494K	Buy	+72,573	New	+$429K	0.03%	1014
2026 Q1	–	Sell	-208,016	Closed	-$1.14M	–	2167
2025 Q4	$1.14M	Sell	208,016 -269,733	-56%	-$1.31M	0.1%	289
2025 Q3	$1.56M	Buy	477,749 +433,059	+969%	+$1.23M	0.13%	163
2025 Q2	$103K	Buy	+44,690	New	+$97.1K	0.01%	1612
2024 Q4	–	Sell	-233,560	Closed	-$469K	–	2040
2024 Q3	$469K	Buy	233,560 +91,755	+65%	+$201K	0.04%	946
2024 Q2	$318K	Buy	+141,805	New	+$413K	0.02%	1247
2023 Q3	–	Sell	-18,077	Closed	-$12K	–	1916
2023 Q2	$12K	Sell	18,077 -9,261	-34%	-$6.71K	﹤0.01%	1453
2023 Q1	$22K	Sell	27,338 -156,519	-85%	-$202K	﹤0.01%	1425
2022 Q4	$416K	Sell	183,857 -52,263	-22%	-$106K	0.05%	714
2022 Q3	$456K	Buy	236,120 +49,640	+27%	+$180K	0.06%	642
2022 Q2	$694K	Buy	186,480 +69,371	+59%	+$275K	0.1%	310
2022 Q1	$764K	Buy	117,109 +76,224	+186%	+$570K	0.1%	297
2021 Q4	$476K	Buy	+40,885	New	+$617K	0.06%	635
2020 Q4	–	Sell	-20,000	Closed	-$448K	–	1600
2020 Q3	$448K	Buy	+20,000	New	+$470K	0.07%	464

Other funds holding TSHA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSA Capital Partners's TSHA Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 72,573 shares worth $494K. The stake represents 0.03% of the portfolio and ranks #1014 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in TSHA as recently as Q4 2025.

GSA Capital Partners first reported a position in TSHA in Q3 2020 and has held it in 14 quarters since. The position peaked at $1.56M in Q3 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

GSA Capital Partners held 72,573 shares of Taysha Gene Therapies worth $494K as of Q2 2026.
Taysha Gene Therapies was a new GSA Capital Partners position in Q2 2026.
Taysha Gene Therapies made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1014 holding.
GSA Capital Partners first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 14 quarters since.
GSA Capital Partners's Taysha Gene Therapies position peaked at $1.56M in Q3 2025.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.